Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Spencer

Showing results (51-60 of 311) with videos related to

Pageof 32
Sort By:
Cancers|June 28, 2019
Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma PatientsMaoshan Chen, Sridurga Mithraprabhu, Malarmathy Ramachandran, et al.
Frontiers in Oncology|June 6, 2022
The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma PracticeRose Turner, Anna Kalff, Krystal Bergin, et al.
Molecular Cancer Therapeutics|May 14, 2017
β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple MyelomaIoanna Savvidou, Tiffany Khong, Andrew Cuddihy, et al.
Leukemia & Lymphoma|December 4, 2020
Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literatureGemma Reynolds, Tamasine Stewart, Simon J Harrison, et al.
British Journal of Haematology|July 26, 2002
Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma riskIan Kerridge, Lisa Lincz, Fiona Scorgie, et al.
Nanoscale Advances|March 2, 2026
Raised or recessed? Finding the optimal gate architecture for improving the static performance of graphene transistorsTzu-Jung Huang, Andrew Spencer, Luke Ingraham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patientsChindu Govindaraj, Peter Tan, Patricia Walker, et al.
British Journal of Haematology|April 8, 2026
HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myelomaElizabeth Hughes, Piers Blombery, Sushmitha Kannan, et al.
Critical Reviews in Oncology/Hematology|February 1, 2022
A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancyJohn Coutsouvelis, Carmela Corallo, Andrew Spencer, et al.
Leukemia Research|September 26, 2006
Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myelomaCindy Baulch-Brown, Timothy J Molloy, Sung Lin Yeh, et al.
Pageof 32

Showing results (51-60 of 311) with videos related to

Sort By:
Pageof 32
Cancers|June 28, 2019
Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma PatientsMaoshan Chen, Sridurga Mithraprabhu, Malarmathy Ramachandran, et al.
Frontiers in Oncology|June 6, 2022
The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma PracticeRose Turner, Anna Kalff, Krystal Bergin, et al.
Molecular Cancer Therapeutics|May 14, 2017
β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple MyelomaIoanna Savvidou, Tiffany Khong, Andrew Cuddihy, et al.
Leukemia & Lymphoma|December 4, 2020
Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literatureGemma Reynolds, Tamasine Stewart, Simon J Harrison, et al.
British Journal of Haematology|July 26, 2002
Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma riskIan Kerridge, Lisa Lincz, Fiona Scorgie, et al.
Nanoscale Advances|March 2, 2026
Raised or recessed? Finding the optimal gate architecture for improving the static performance of graphene transistorsTzu-Jung Huang, Andrew Spencer, Luke Ingraham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patientsChindu Govindaraj, Peter Tan, Patricia Walker, et al.
British Journal of Haematology|April 8, 2026
HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myelomaElizabeth Hughes, Piers Blombery, Sushmitha Kannan, et al.
Critical Reviews in Oncology/Hematology|February 1, 2022
A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancyJohn Coutsouvelis, Carmela Corallo, Andrew Spencer, et al.
Leukemia Research|September 26, 2006
Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myelomaCindy Baulch-Brown, Timothy J Molloy, Sung Lin Yeh, et al.
Pageof 32